2026-10-14T03:24:50Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33958397 2026-09-21T17:53:49Z category_7 category_8 category_15 category_21 category_272 category_46 category_734 category_64 category_106 category_132 category_134 category_135 portal_5 item_type_3 month_year_09_2026

<p>Fasta files of the 3 SHUV RTPCR positive samples.</p> Matshepo Elizabeth Rakaki (25084955) Adriano Mendes (4379425) Paul Wichgers Schreur (25084958) Martin H. Groschup (69888) Markus Keller (316671) Nicolette Marie Du Plessis (25084961) Maryke De Villier (25084964) Theunis Avenant (773260) Marietjie Venter (552145) Medicine Microbiology Neuroscience Biotechnology Environmental Sciences not elsewhere classified Immunology Biological Sciences not elsewhere classified Cancer Science Policy Infectious Diseases Virology Computational Biology reemerging zoonotic orthobunyavirus peribunyaviridae family associated past 10 years healthy control groups 2019 &# 8211 without neurological signs established using baculovirus identify acute infections acute neurological infections 84 %) afduc 7 %) afduc igg elisa assay shuni virus infections orthobunyavirus quantitative rt molecular diagnostic assays shuv neutralising antibodies neurological infections using molecular diagnostic assays igg elisa acute fever 8 %) 00 %) igg elisas igm elisa shuv infections unknown cause two provinces positive sera partially due neutralization tests mpumalanga provinces missed cause middle east findings suggest expressed glycoproteins establish serologic epidemiological investigation clinical epidemiology clinical cases clinical awareness birth defects based surveillance arbovirus season <div><p>Shuni Virus (SHUV) is a reemerging zoonotic orthobunyavirus in the Peribunyaviridae family associated with neurological infections and birth defects in humans and animals in Africa and has emerged in the Middle East in the past 10 years. Limited epidemiological data exist in humans, partially due to a lack of clinical awareness and availability of diagnostic assays to determine the incidence of clinical cases and seroprevalence in the population. The goal of this study was to establish serologic and molecular diagnostic assays for SHUV for hospital-based surveillance and to investigate the clinical epidemiology in humans in South Africa. The incidence of SHUV infections was investigated in patients with acute fever of unknown cause with or without neurological signs (AFDUC/N) during the arbovirus season (January-June, 2019–2021). IgM and IgG ELISAs for SHUV were established using baculovirus-expressed glycoproteins and validated against virus-neutralization tests (VNT) positive sera. Orthobunyavirus quantitative RT-PCR (RT-qPCR) and IgM ELISA were used to identify acute infections, and IgG ELISA to define the seroprevalence in patients and healthy control groups in hospitals in Gauteng and Mpumalanga provinces in South Africa. In total, 3/349 (0.84%) AFDUC/N cases tested positive by RT-qPCR and confirmed as SHUV by sequencing. In total, 22/225 (9.7%) AFDUC/N patients had SHUV neutralising antibodies (VNT), of which 11/22 (50.00%) were IgM positive, with an IgM seropositivity of 4.89% (11/225 (4.89%)). Of the RT-PCR and double IgM + VNT+ patients, 60% presented with seizures and 40% with meningitis, of which 36.36% were children and 63.63% were adults, respectively. In total, 9/112 (8%) of the healthy control group tested positive on the IgG ELISA assay. These findings suggest that SHUV is a missed cause of acute neurological infections in hospitalized children and adults in South Africa and should be investigated in humans in Africa and other regions.</p></div> 2026-09-21T17:59:09Z Dataset Dataset 10.1371/journal.pntd.0014738.s002 https://figshare.com/articles/dataset/_p_Fasta_files_of_the_3_SHUV_RTPCR_positive_samples_p_/33958397 CC BY 4.0